Systemic Mastocytosis
19
2
2
11
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
15.8%
3 terminated out of 19 trials
78.6%
-7.9% vs benchmark
11%
2 trials in Phase 3/4
55%
6 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (19)
Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis
Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Use of Tamoxifen in Systemic Mastocytosis
Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Treatment of Indolent Systemic Mastocytosis With PA101
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Imatinib in KIT-negative Systemic Mastocytosis
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
Obatoclax for Systemic Mastocytosis
Evaluation of Response of Dasatinib to Treat Mastocytosis